Sugi Predict

Sugi Predict / Compounds / SCHEMBL4178458

SCHEMBL4178458

SCHEMBL4178458

CC(C)(C)OC(=O)Nc1cccc(Nc2nc(Cl)ncc2C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.56
▸ EGFR P00533 11/20 0.51
▸ BTK Q06187 3/20 0.47
▸ BRD4 O60885 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ ERBB2 P04626 2/20 0.45
▸ ERBB3 P21860 2/20 0.45
▸ ERBB4 Q15303 2/20 0.45
▸ CDK1 P06493 1/20 0.44
▸ PTK2 Q05397 2/20 0.44
▸ SRC P12931 1/20 0.44
▸ AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537279 1.00 SYK (0.56) SYKEGFRBTKBRD4JAK2
SCHEMBL12518613 0.87 SYK (0.71) SYKEGFRBRD4
SCHEMBL4180112 0.87 SYK (0.57) SYKEGFRBTKBRD4JAK3
SCHEMBL9923768 0.86 SYK (0.56) SYKEGFRBTKBRD4JAK3
SCHEMBL30306552 0.86 SYK (0.56) SYKEGFRBTKBRD4JAK3
SCHEMBL17197435 0.86 EGFR (0.52) SYKEGFRBTKJAK2JAK3
SCHEMBL28446232 0.86 SYK (0.54) SYKEGFRBRD4CDK1SRC
SCHEMBL13166506 0.86 SYK (0.67) SYKEGFRBTKJAK2JAK3
SCHEMBL29537421 0.85 SYK (0.55) SYKEGFRBRD4CDK1SRC
SCHEMBL4166343 0.85 SYK (0.55) SYKEGFRBTKBRD4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218704-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2022-07-14 — — US disclosed
WO-2022094354-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF LENGO THERAPEUTICS, INC. (US) 2022-05-05 — — WO disclosed
EP-2825041-B1 SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR CELGENE CAR LLC (BM) 2021-04-21 — — EP disclosed
US-10946016-B2 Solid forms of an epidermal growth factor receptor kinase inhibitor CELGENE CAR LLC (BM) 2021-03-16 — — US disclosed
US-20210017137-A1 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR BRISTOL-MYERS SQUIBB COMPANY 2021-01-21 — — US disclosed
US-20200276194-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2020-09-03 — — US disclosed
US-10710979-B2 EGFR kinase inhibitor and preparation method and use thereof ZHEJIANG BOSSAN PHARMACEUTICAL CO. LTD. (CN) 2020-07-14 — — US disclosed
US-10570099-B2 Salts of an epidermal growth factor receptor kinase inhibitor CELGENE CAR LLC (BM) 2020-02-25 — — US disclosed
US-10434101-B2 Heterocyclic compounds and uses thereof CELGENE CAR LLC (BM) 2019-10-08 — — US disclosed
US-10300058-B2 Tyrosine kinase inhibitor and uses thereof Xuanzhu Pharma Co., Ltd. (CN) 2019-05-28 — — US disclosed
US-20130267530-A1 SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR BRISTOL-MYERS SQUIBB COMPANY 2013-10-10 — — US disclosed
US-20130267531-A1 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR CELGENE AVILOMICS RESEARCH, INC. (US) 2013-10-10 — — US disclosed
WO-2013138495-A1 SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR CELGENE AVILOMICS RESEARCH, INC. (US) 2013-09-19 — — WO disclosed
WO-2013138502-A1 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR CELGENE AVILOMICS RESEARCH, INC. (US) 2013-09-19 — — WO disclosed
US-20120157426-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-21 — — US disclosed
US-20120149687-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-14 — — US disclosed
US-20120149722-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-06-14 — — US disclosed
WO-2012064706-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-05-18 — — WO disclosed
WO-2012061299-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-05-10 — — WO disclosed
WO-2012061303-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10434101-B2 Heterocyclic compounds and uses thereof ABCG2, CYP3A5, CYP3A43 SYK 2551/4885EGFR 2849/4885BTK 988/4885
US-20220218704-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 SYK 2551/4885EGFR 2849/4885BTK 988/4885
US-20200276194-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 SYK 2551/4885EGFR 2849/4885BTK 988/4885
US-10946016-B2 Solid forms of an epidermal growth factor receptor kinase inhibitor EGFR, ERBB2, ERBB3 SYK 296/4885EGFR 1/4885BTK 124/4885
US-10300058-B2 Tyrosine kinase inhibitor and uses thereof EGFR, ERBB2, ABL1 SYK 20/4885EGFR 1/4885BTK 25/4885
US-20120149687-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 SYK 2551/4885EGFR 2849/4885BTK 988/4885
US-10710979-B2 EGFR kinase inhibitor and preparation method and use thereof EGFR, ERBB2, ERBB4 SYK 227/4885EGFR 1/4885BTK 33/4885
US-20210017137-A1 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR EGFR, ERBB2, ERBB4 SYK 332/4885EGFR 1/4885BTK 129/4885
US-20120149722-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 SYK 2370/4885EGFR 1981/4885BTK 594/4885
US-20130267531-A1 SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR EGFR, ERBB2, ERBB4 SYK 332/4885EGFR 1/4885BTK 129/4885
US-20130267530-A1 SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR EGFR, ERBB2, ERBB3 SYK 296/4885EGFR 1/4885BTK 124/4885
US-20120157426-A1 MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF EGFR, ERBB3, ERBB2 SYK 548/4885EGFR 1/4885BTK 46/4885
US-10570099-B2 Salts of an epidermal growth factor receptor kinase inhibitor EGFR, ERBB2, ERBB4 SYK 332/4885EGFR 1/4885BTK 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.